Presentation is loading. Please wait.

Presentation is loading. Please wait.

Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann.

Similar presentations


Presentation on theme: "Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann."— Presentation transcript:

1 Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann EUROPEAN COMMISSION Enterprise Directorate-General Pharmaceuticals Unit

2 Richtlinie 2001/20/EG DES EUROPÄISCHEN PARLAMENTS UND DES RATES Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001and published 1/5/2001

3 Directive 2001/20/EC Objectives: Protection of subjects participating in clinical trials Information on clinical trials - including database Single decision by competent authorities Single decision by Ethics Committees Good Manufacturing Practice (GMP) Good Clinical Practice (GCP)

4 Directive 2001/20/EC Article 22  Implementation in national legislation AT ? IR ? BE ? IT DK LU ? DE ? NL ? EL ? PO ? ES SE FI ? UK ? FR ?

5 Directive 2001/20/EC Article 1Good clinical practice → new Directive&Guideline Articles Ethics Committee → guidance Article 9Competent authorities → guidance Article 11Eudract database, Exchanges of information → guidance Article 13.1 Manufacturing/importation authorisation requirements for investigational medicinal products → new Directive&Guideline requirements for investigational medicinal products → new Directive&Guideline Article 15 Inspections (Inspection procedure, Qualification of inspector) and Master file on the trial and archiving → new Directive&Guideline Article 17 Eudravigilance database → guidance

6 Directive 91/356/EC replaced by  Directive 2003/94/EC of 8 October 2003  Directive 2003/94/EC of 8 October 2003 OJ L 262/  Annex 13  Annex 13 Manufacture of investigational medicinal products Manufacture of investigational medicinal products up-dated and published July 2003 up-dated and published July 2003 Directive on Good Manufacturing Practice

7 The interaction between the Ethics Committees, Competent Authority and Sponsor and in the European Medicinal Product Legislation – before starting a clinical trial SPONSOR Ethics Committee Start of the Trial Investigator/Applicnat Competent Authority

8 The interaction between the Ethics Committees, Competent Authority and Sponsor and in the European Medicinal Product Legislation - during conducting a clinical trial SPONSOR Ethics Committee Investigator Amendments/ end of trial suspension/ Adverse reactions Competent Authority Competent Authority Investigator Ethics Committee Competent Authority Investigator

9 Detailed guidance on the application format and documentation to be submitted in an application for an ethics committee opinion on a clinical trial on a medicinal product for human use Detailed guidance for the request for the authorisation of a clinical trial on a medicinal product for human use to the competent authorities in the European Union, notification of substantial amendments and clarification of the end of a clinical Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use Guidance published 23 April 2003 Commission web-site  under review

10 Directive 2001/20/EC and Guidance Documents   Harmonisation: Time-line for opinion by Ethics Committees (EC) Time-line for ‘authorisation’ by competent authorities (CA) Application Form to EC and CA Information on content of the dossier

11 Detailed guidance on the European clinical trial data base (Application form to EC and CA) Detailed guidance on the European database of Suspected Unexpected Serious Adverse Reactions Guidance published 23 April 2003 Commission web-site  under review

12 The European clinical trial data base & European database of Suspected Unexpected Serious Adverse Reactions European database

13  Dataset requires for allocation of a EudraCT number  Minimum core dataset for EudraCT: 1 May 2004  Full acting system in place: 2005 European database  Pilot-phase finalised

14  Dataset for Eudravigilance database  Definition of inclusion of information in Clinical Trials Database OR Pharmacovigilance database Trials Database OR Pharmacovigilance database for medicinal products with MA European database

15  Directive 2001/20/EC = Member States, the Agency and the Commission ONLY  Regulation (EC) No …/2003/EC Article 57 (1) (k) creating a database on medicinal products to be accessible to the general public Article 57 (2) … Where appropriate, the database shall also include references to data on clinical trials currently carried out or already completed, contained in the clinical trials database for in Article 11 of Directive 2001/20/EC. The Commission shall, in consultation with the Member States, issue guidelines on data fields which could be included and which may be accessible to the public European database

16 Directive on Good Clinical Practice  Good Clinical Practice  Manufacture and import of investigational medicinal products medicinal products  Trial Master File and Archiving  Qualification of GCP inspectors  GCP Inspection procedures Directive/Guidelines  awaited

17 Directive 2001/20/EC   Concerns raised by academic and researchers Definition of Sponsor and responsibilities of the sponsor Requirements of GMP Bureaucraties

18  Increased data requirements and application details compared to old system  but unified format and contents of application  Pharmacovigilance reporting system  different/selective approaches pointed out in guidance documents  Medicinal Product in accordance with Good Manufacturing Process  Patient need assurance of high quality of medicinal product Directive 2001/20/EC

19 Herzlichen Dank


Download ppt "Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann."

Similar presentations


Ads by Google